Leadership Overview
Novotech has 9 executives leading key functions including strategy, operations, finance, medical affairs, marketing, human resources, legal, and ownership.
Driven by a commitment to innovation, Novotech partners with biotech companies to accelerate the development of advanced and novel therapeutics, impacting global health outcomes.
Driven by a commitment to innovation, Novotech partners with biotech companies to accelerate the development of advanced and novel therapeutics, impacting global health outcomes.
Leadership Roles at Novotech
John Moller - Chief Executive Officer
John Moller, the Chief Executive Officer at Novotech, directs the overarching corporate strategy and global operations. Moller guides Novotech's mission to accelerate the development of novel therapeutics by fostering strategic partnerships with biotech firms worldwide. This leadership involves setting the company's long-term vision and ensuring alignment across all functional areas to drive innovation and market expansion. The Chief Executive Officer's role is critical in navigating the complex landscape of clinical research and development, positioning Novotech as a premier full-service CRO. John Moller's strategic direction ensures the company consistently meets the evolving needs of its biotech partners, facilitating the advancement of cutting-edge treatments from early-phase research through to regulatory submission. This executive leadership ensures operational excellence and sustained growth within the global biopharmaceutical sector.
Ekaterina Galperina - Chief Financial Officer
Ekaterina Galperina, the Chief Financial Officer at Novotech, manages all financial aspects of the organization, including financial planning, risk management, and reporting. Galperina ensures robust financial health and provides strategic financial guidance to support Novotech's growth initiatives and partnerships with biotech companies. The Chief Financial Officer's oversight extends to budgeting, forecasting, and capital allocation, crucial for funding the acceleration of novel therapeutic development. This executive leadership is vital for maintaining investor confidence and ensuring the financial sustainability of the company's global operations. Ekaterina Galperina's financial acumen supports Novotech's mission by enabling strategic investments in research and development infrastructure. The Chief Financial Officer's role involves optimizing financial performance and ensuring compliance with all relevant financial regulations across international markets.
Hussein AlRoz - Chief Operating Officer
Hussein AlRoz, the Chief Operating Officer at Novotech, oversees the execution of global operational strategies and day-to-day business activities. AlRoz ensures the efficient delivery of comprehensive clinical research services to biotech partners, managing project timelines, resource allocation, and quality control across all phases of therapeutic development. The Chief Operating Officer's responsibilities include optimizing internal processes and enhancing operational capabilities to support the acceleration of novel treatments. This executive leadership focuses on maintaining high standards of service delivery and operational excellence throughout Novotech's global footprint. Hussein AlRoz drives the implementation of best practices in clinical trial management, ensuring seamless collaboration between Novotech's teams and its clients. The Chief Operating Officer's focus on operational efficiency directly contributes to the successful and timely progression of advanced therapeutics through the development pipeline.
Funsho Ojebuoboh - President & Owner
Funsho Ojebuoboh, the President & Owner at Novotech, holds ultimate responsibility for the company's strategic direction and overall success. Ojebuoboh drives the vision for Novotech's continued growth and its pivotal role in partnering with biotech firms to accelerate the development of advanced therapeutics. The President & Owner's leadership ensures that the company remains at the forefront of clinical research innovation. This executive's influence shapes the organizational culture and strategic priorities, fostering an environment conducive to groundbreaking scientific advancement. Funsho Ojebuoboh's ownership stake underscores a deep commitment to Novotech's mission and its impact on global health. The President & Owner's strategic oversight guarantees sustained focus on delivering exceptional value to clients and advancing novel treatments.
Joseph Dumais - President
Joseph Dumais, the President at Novotech, contributes to the executive leadership team by focusing on key strategic initiatives and operational oversight. Dumais supports Novotech's mission to partner with biotech companies, accelerating the development of novel therapeutics through comprehensive clinical research services. The President's role involves driving business development and ensuring the effective implementation of corporate strategies across global markets. This executive leadership enhances Novotech's capacity to manage complex clinical trials and deliver high-quality results. Joseph Dumais's contributions are vital to maintaining Novotech's competitive edge and expanding its reach within the biopharmaceutical industry. The President's focus on strategic growth and operational excellence supports the company's commitment to advancing medical breakthroughs.
Melinda Borrelli - Head of Medical Office Chief & Chief Marketing Officer, Operations
Melinda Borrelli, the Head of Medical Office Chief & Chief Marketing Officer, Operations at Novotech, directs both the strategic medical affairs and the comprehensive marketing initiatives. Borrelli ensures that Novotech's clinical research services effectively meet the complex medical and scientific needs of biotech partners developing novel therapeutics. This dual leadership role involves shaping the company's market presence and communicating its value proposition to a global audience. The Head of Medical Office Chief & Chief Marketing Officer, Operations' responsibilities include overseeing medical strategy development and executing marketing campaigns that highlight Novotech's expertise in accelerating drug development. Melinda Borrelli's leadership ensures strong market positioning and effective engagement with the biopharmaceutical industry. This executive drives the integration of medical insights with marketing strategies to support the company's mission.
Tim Bray - Chief Human Resources Officer
Tim Bray, the Chief Human Resources Officer at Novotech, leads all human capital management strategies, focusing on talent acquisition, development, and retention. Bray ensures Novotech cultivates a high-performing workforce capable of supporting the complex needs of biotech companies in accelerating therapeutic development. The Chief Human Resources Officer's role is critical in fostering a positive and productive organizational culture that aligns with Novotech's mission. This executive leadership oversees employee relations, compensation and benefits, and organizational design to support global operations. Tim Bray's strategic approach to human resources strengthens Novotech's ability to attract and retain top talent in the competitive CRO industry. The Chief Human Resources Officer's initiatives are essential for building a skilled and motivated team dedicated to advancing novel treatments.
Judith Ng-Cashin - Chief Medical Officer
Judith Ng-Cashin, the Chief Medical Officer at Novotech, provides critical medical and scientific leadership, guiding the strategic direction of clinical development programs. Ng-Cashin ensures that Novotech's services align with the highest medical standards, supporting biotech partners in accelerating the development of advanced and novel therapeutics. The Chief Medical Officer's expertise is essential in navigating regulatory pathways and optimizing clinical trial design for maximum efficacy and patient safety. This executive leadership role involves close collaboration with clients and internal teams to translate scientific insights into successful clinical outcomes. Judith Ng-Cashin's medical guidance is fundamental to Novotech's mission of advancing cutting-edge treatments. The Chief Medical Officer's focus on scientific rigor and clinical excellence reinforces Novotech's position as a trusted CRO partner.
Kristin Brown - Chief Legal Officer
Kristin Brown, the Chief Legal Officer at Novotech, oversees all legal affairs and ensures compliance with global regulatory requirements. Brown provides strategic legal counsel to support Novotech's partnerships with biotech companies and the acceleration of novel therapeutic development. The Chief Legal Officer's responsibilities include managing contracts, intellectual property, and risk mitigation across international operations. This executive leadership ensures that Novotech operates within the highest ethical and legal standards, safeguarding the company and its clients. Kristin Brown's legal expertise is crucial for navigating the complex legal frameworks inherent in clinical research and development. The Chief Legal Officer's diligent oversight protects Novotech's interests and facilitates smooth business operations worldwide.
Explore Leadership Teams in Business Services
PAREXEL International Corporation, a biopharmaceutical outsourcing services company, provides clinical research and logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting Services (PC), and PAREXEL Informatics (PI). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management, and biostatistical analysis, epidemiology and health economics/outcomes research, clinical supply and drug logistics, pharmacovigilance, commercialization, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. The PC segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, commercialization, and strategic compliance; and market and product development, and targeted communications services to support product launch, as well as offers solutions to address client issues associated with product development, registration, and commercialization. The PI segment provides information technology solutions comprising ClinPhone randomization and trial supply management solutions, medical imaging services, IMPACT clinical trial management systems, LIQUENT InSight regulatory information management software and professional services, DataLabs electronic data capture systems, Web-based portals, systems integration services, electronic patient reported outcomes, and patient diary applications, as well as centralized assessment services for patient technology solutions. PAREXEL International Corporation was founded in 1983 and is headquartered in Waltham,...
Company Leadership DT
PA
Canadian Nuclear Laboratories (CNL) is Canadas premier nuclear science and technology organization. CNL has been a world leader in developing peaceful and innovative applications from nuclear technology through its expertise in physics, metallurgy, chemi
Company Leadership ML
HC
Embrapa (Brazilian Agricultural Research Corporation) is a Brazilian public research institution headquartered in Brasilia, Brazil. Founded in 1973 and linked to the Ministry of Agriculture, Embrapa conducts agricultural research and development to improve productivity, sustainability, and competitiveness of Brazilian agriculture. The organization operates a network of research centers across Brazil.
Company Leadership SM
RC
FO
Founded in 1985, Pharmaceutical Product Development (PPD) is a contract research organization engaging in drug discovery, development and lifecycle management for clients from pharmaceutical, biotechnological, medical device, academic and government organizations.
Company Leadership LE
FS
MW
Frequently Asked Questions Regarding Novotech Top Executives and Leadership Team
